PL3337820T3 - Ulepszony sposób ponownego fałdowania fragmentów przeciwciał - Google Patents

Ulepszony sposób ponownego fałdowania fragmentów przeciwciał

Info

Publication number
PL3337820T3
PL3337820T3 PL16766389T PL16766389T PL3337820T3 PL 3337820 T3 PL3337820 T3 PL 3337820T3 PL 16766389 T PL16766389 T PL 16766389T PL 16766389 T PL16766389 T PL 16766389T PL 3337820 T3 PL3337820 T3 PL 3337820T3
Authority
PL
Poland
Prior art keywords
refolding
antibody fragments
improved method
fragments
antibody
Prior art date
Application number
PL16766389T
Other languages
English (en)
Inventor
Sandeep Somani
Ashish Pandey
Ashok Mishra
Rustom Sorab Mody
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of PL3337820T3 publication Critical patent/PL3337820T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16766389T 2015-08-17 2016-08-17 Ulepszony sposób ponownego fałdowania fragmentów przeciwciał PL3337820T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3118MU2015 2015-08-17
EP16766389.7A EP3337820B1 (en) 2015-08-17 2016-08-17 An improved refolding process for antibody's fragments
PCT/IB2016/054926 WO2017029620A1 (en) 2015-08-17 2016-08-17 An improved refolding process for antibody's fragments

Publications (1)

Publication Number Publication Date
PL3337820T3 true PL3337820T3 (pl) 2021-11-22

Family

ID=56936450

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16766389T PL3337820T3 (pl) 2015-08-17 2016-08-17 Ulepszony sposób ponownego fałdowania fragmentów przeciwciał

Country Status (19)

Country Link
US (1) US10781250B2 (pl)
EP (1) EP3337820B1 (pl)
JP (1) JP6755939B2 (pl)
CN (1) CN108026165A (pl)
AU (1) AU2016307976A1 (pl)
CA (1) CA2993907A1 (pl)
DK (1) DK3337820T3 (pl)
ES (1) ES2843558T3 (pl)
HK (1) HK1254752A1 (pl)
HR (1) HRP20210067T1 (pl)
HU (1) HUE052993T2 (pl)
LT (1) LT3337820T (pl)
MX (1) MX394263B (pl)
PH (1) PH12018500362B1 (pl)
PL (1) PL3337820T3 (pl)
PT (1) PT3337820T (pl)
RU (1) RU2018109102A (pl)
WO (1) WO2017029620A1 (pl)
ZA (1) ZA201801498B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
MX2019011343A (es) * 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
EP3624847A1 (en) * 2017-05-19 2020-03-25 Council of Scientific and Industrial Research A method for producing refolded recombinant humanized ranibizumab
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
CN111128293B (zh) * 2019-11-25 2020-11-10 苏州纽博立科技有限公司 一种抗体药物生产工艺中碎片的修复方法
CN113073092A (zh) * 2021-04-15 2021-07-06 宁波瑞林生物科技有限公司 重组人组织型激肽释放酶及其制备方法
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
WO2006058890A2 (en) * 2004-11-30 2006-06-08 Novo Nordisk A/S Method of producing antibodies
CN100336824C (zh) * 2005-12-19 2007-09-12 百奥泰生物科技(广州)有限公司 一种重组蛋白的高效变复性的方法
ES2603399T3 (es) * 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
CN101506222B (zh) * 2006-07-14 2013-10-02 健泰科生物技术公司 重组蛋白的重折叠
CN102089319B (zh) * 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
CN102206272B (zh) * 2009-12-11 2014-10-01 普罗特奥姆技术公司 生产重组α1-抗胰蛋白酶的方法
CA2815342A1 (en) * 2010-10-20 2012-04-26 Medimmune, Llc Methods for processing inclusion bodies
US10065987B2 (en) * 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
CN103804486B (zh) * 2014-01-20 2017-05-17 安徽安科生物工程(集团)股份有限公司 一种提高重组人干扰素α2b天然构象含率的制备工艺

Also Published As

Publication number Publication date
HRP20210067T1 (hr) 2021-03-05
MX2018001994A (es) 2018-11-09
ES2843558T3 (es) 2021-07-19
JP2018529654A (ja) 2018-10-11
HUE052993T2 (hu) 2021-06-28
RU2018109102A3 (pl) 2020-01-30
EP3337820B1 (en) 2020-10-14
JP6755939B2 (ja) 2020-09-16
EP3337820A1 (en) 2018-06-27
ZA201801498B (en) 2018-12-19
PH12018500362B1 (en) 2022-08-05
AU2016307976A1 (en) 2018-03-08
WO2017029620A1 (en) 2017-02-23
US10781250B2 (en) 2020-09-22
CA2993907A1 (en) 2017-02-23
PT3337820T (pt) 2021-01-19
DK3337820T3 (da) 2021-01-18
PH12018500362A1 (en) 2018-08-29
CN108026165A (zh) 2018-05-11
HK1254752A1 (zh) 2019-07-26
US20180230206A1 (en) 2018-08-16
RU2018109102A (ru) 2019-09-19
MX394263B (es) 2025-03-24
LT3337820T (lt) 2021-02-10

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL250566B2 (en) Anti-lag3 antibodies and antigen-binding fragments
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
DK3313882T3 (da) Anti-VISTA antistoffer og fragmenter
IL251970B (en) Anti-cd79b antibodies and methods of use
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
DK3344654T3 (da) Anti-lag-3-antistoffer
EP3319984C0 (en) TAU LINKING ANTIBODIES
PL3167096T3 (pl) Dwuetapowy sposób nanoszenia
DK3310812T3 (da) Anti-HER2-antistoffer og fremgangsmåder til anvendelse
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
IL272851A (en) Methods of using dipivefrin
EP3319983C0 (en) TAU LINKING ANTIBODIES
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
HUE060878T2 (hu) Anti-transztiretin antitestek
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
LT3152176T (lt) Cemento mišinio gamybos būdas
DK3250593T3 (da) Anti-transthyretin-antistoffer
IL268731A (en) New uses of anti-sirpg antibodies
DK3368578T3 (da) Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf
LT3237432T (lt) Baltymo gamyba